Results from the LIVE-AIR Phase 3 Randomized Double-Blind Placebo-Controlled Trial

Ifabotuzumab Phase 1 Results

Solebury Trout Talks: Interview with Dale Chappell, Humanigen - Part of the Nametag Series

ASH 2020 ZUMA-19 Poster

The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome

Op-Ed: Vaccine race creates blind spots

ZUMA-19 Abstract Accepted for Presentation at ASH 2020 Annual Meeting

Mayo Clinic Proceedings Lenzilumab COVID-19 Case-Cohort Study

GM-CSF and Cytokine Storm in Coronavirus

A new role for an old cytokine: GM-CSF amplifies GVHD

Role of GM-CSF in acute GVHD

Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF–licensed myeloid cells

Lenzilumab Study Published in ‘blood’

Humanigen GM-CSF Review

Lenzilumab at ASH 2018 - Abstract

Targeting EphA3 Inhibits Cancer Growth by Disrupting the Tumor Stromal Microenvironment

EphA3 Publication in 'Cancers'

Hypoxia-Controlled EphA3 Marks a Human Endometrium-Derived Multipotent Mesenchymal Stromal Cell that Supports Vascular Growth

Eosinophil surface receptor EMR1: a novel therapeutic target for eosinophilic disorders